Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer DB Revenue Type — Royalty Revenues by Quarter
DB Revenue Type — Royalty Revenues ($M) ($M)
Pfizer DB Revenue Type — Royalty Revenues: $474M in Q2 2026, up 11.3% from a year earlier.
Latest, Q2 2026
474
Period ended Jun 28, 2026
Change on a year earlier
+11.3%
426 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
10
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Database (SEC Form 10-K / 10-Q XBRL via lib/db.py).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Revenue Type — Royalty Revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 474 | +11.3% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 396 | +28.6% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 480 | +11.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | 436 | +13.5% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 426 | +23.5% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 308 | +17.1% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 431 | +34.3% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 29, 2024 | 384 | +47.7% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 345 | +26.4% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 263 | +28.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 321 | – | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2023 | Oct 1, 2023 | 260 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jul 2, 2023 | 273 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Apr 2, 2023 | 204 | – | Form 10-Q (filed 2024-05-08) ↗ |
Cite this data
StockData. (2026). Pfizer DB Revenue Type — Royalty Revenues ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/db-prod-royalty
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.